Sorin Ebinger-Armeanu

Hoppe Seyler Str. 3
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival.

Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival.

Journal: Biology

Published: November 03, 2025

Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults.

Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 23, 2025

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation.

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation.

Journal: Frontiers in oncology

Published: April 26, 2025

Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

Journal: British journal of cancer

Published: January 23, 2025

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion.

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion.

Journal: Frontiers in oncology

Published: November 13, 2024

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: July 25, 2024

Benchmarking whole exome sequencing in the German network for personalized medicine.

Benchmarking whole exome sequencing in the German network for personalized medicine.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 20, 2024

Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.

Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.

Journal: Vaccines

Published: March 14, 2024

Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition.

Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition.

Journal: Nature communications

Published: November 23, 2023

UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents.

UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents.

Journal: EBioMedicine

Published: May 19, 2023

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.

Journal: NPJ precision oncology

Published: April 03, 2023

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.

Journal: Neuro-oncology advances

Published: March 14, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026